The primary objective of this proposal is to continue to support and expand Mayo Clinic's participation in the activities of Childrens Cancer Group through: 1.) Evaluating new cancer chemotherapeutic agents and developing new approaches to treatment of children with cancer by, a) maintaining a leadership role in CCG Phase II and New Agent Study Committees, b) performing pilot studies for potential incorporation into future randomized CCG trials, c) entering patients on new agent studies, d) utilizing the resources in Doctor Ames' pharmacology laboratory to evaluate the pharmacology and pharmacokinetics of cancer chemotherapy. 2.) Improving treatment and potential for cure of various childhood cancers and leukemias by, a) continuing to enter patients into CCG treatment protocols with the expectation that study entries will increase as new studies for various tumor systems are activated, b) playing a leadership role in CCG Strategy Groups in order to develop new approaches to the treatment of childhood cancer, c) participating in the development of new randomized trials for the treatment of specific diseases and maintaining active participation in CCG study committees by Mayo investigators currently assigned to study committees d) studying long-term effects of treatment. 3.) Studying the biology and epidemiology of childhood cancer by, a) active participation in regional and CCG case-control epidemiology studies, b) making available to CCG the skills and resources of Mayo investigators in Pathology, Immunology, Molecular Biology, Cytogenetics and other areas of basic and applied laboratory research. 4.) Improving supportive care of children with cancer by, a) continued participation in CCG supportive care studies, b) standardization of drug administration procedures for various chemotherapeutic agents, c) development and evaluation of methods for measuring and controlling cancer-related and procedure-related pain. 5.) Providing access for patients in outlying areas to these clinical research programs through affiliates in Des Moines, Iowa; Fargo, North Dakota; Duluth, Minnesota; Regina and Saskatoon, Saskatchewan; and Sioux Falls, South Dakota.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA028882-17
Application #
2007312
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1981-01-01
Project End
1998-11-30
Budget Start
1996-12-01
Budget End
1997-11-30
Support Year
17
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Seitzman, Robin L; Glover, Dorie A; Meadows, Anna T et al. (2004) Self-concept in adult survivors of childhood acute lymphoblastic leukemia: a cooperative Children's Cancer Group and National Institutes of Health study. Pediatr Blood Cancer 42:230-40
Shamberger, Robert C; LaQuaglia, Michael P; Gebhardt, Mark C et al. (2003) Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann Surg 238:563-7; discussion 567-8
Casillas, Jacqueline N; Woods, William G; Hunger, Stephen P et al. (2003) Prognostic implications of t(10;11) translocations in childhood acute myelogenous leukemia: a report from the Children's Cancer Group. J Pediatr Hematol Oncol 25:594-600
Davies, Stella M; Bhatia, Smita; Ross, Julie A et al. (2002) Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood 100:67-71
Wells, Robert J; Reid, Joel M; Ames, Matthew M et al. (2002) Phase I trial of cisplatin and topotecan in children with recurrent solid tumors: Children's Cancer Group Study 0942. J Pediatr Hematol Oncol 24:89-93
Lange, Beverly J; Bostrom, Bruce C; Cherlow, Joel M et al. (2002) Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 99:825-33
Ou, Shu Xiao; Han, Dehui; Severson, Richard K et al. (2002) Birth characteristics, maternal reproductive history, hormone use during pregnancy, and risk of childhood acute lymphocytic leukemia by immunophenotype (United States). Cancer Causes Control 13:15-25
Cairo, M S; Krailo, M D; Morse, M et al. (2002) Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate ('Orange') in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: a children's cancer group report. Leukemia 16:594-600
Wells, R J; Arthur, D C; Srivastava, A et al. (2002) Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children's Cancer Group Study 213. Leukemia 16:601-7
Arndt, C A; Krailo, M D; Liu-Mares, W et al. (2001) Phase I study of CI-958 in children and adolescents with recurrent solid tumors. Cancer 91:1166-9

Showing the most recent 10 out of 22 publications